KILLER/DR5, a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor gene, has been shown to be induced by DNA damaging agents and radiation in a p53-dependent manner. Although TRAIL is a potential therapeutic agent for cancer, the induction mechanism of its receptors is poorly understood. Here we show the identi®cation of three p53 DNA-binding sites in the KILLER/DR5 genomic locus located upstream (BS1; 70.82 Kb) of the ATG site, within Intron 1 (BS2; +0.25 Kb downstream of the ATG) and within Intron 2 (BS3; +1.25 Kb downstream of the ATG). A modi®ed p53-binding and immunoselection protocol using a wildtype p53-expressing adenovirus vector (Ad-p53) was used to identify the binding sites and to show that each binding site can bind speci®cally to wild-type p53 protein (wt-p53). A reporter assay revealed that only BS2 could enhance luciferase expression driven by a basal promoter. We constructed a reporter plasmid carrying the genomic regulatory region of KILLER/DR5 including the three p53 DNA-binding sites but no additional basal promoter. The genomic fragment showed basal transcriptional activity which was induced by wt-p53 but not by mutant p53, and human papilloma virus E6 inhibited the p53-dependent activation. Mutation of BS2 abrogated not only the binding activity of wt-p53 but also the induction of the KILLER/DR5 genomic promoter-reporter gene, indicating that BS2 is responsible for the p53-dependent transactivation of KILLER/ DR5. In p53-wild-type but not -mutant or -null cell lines, doxorubicin treatment stabilized p53 protein, and increased speci®c binding to BS2 as revealed by EMSA, and upregulated the KILLER/DR5 promoter-luciferase reporter gene. These results suggest that the transactivation of KILLER/DR5 is directly regulated by exogenous or endogenous wt-p53 and establishes KILLER/DR5 as a p53 target gene that can signal apoptotic death.
Introduction
TRAIL is a cytokine of the TNF family which is expressed in most adult human tissues and is capable of killing transformed but not normal cells of dierent origins in a p53-independent manner (Pitti et al., 1996; Wiley et al., 1995; Kim et al., 2000) through binding to two proapoptotic receptors, DR4 and KILLER/DR5 (Chaudhary et al., 1997; MacFarlane et al., 1997; Screaton et al., 1997; Sheikh et al., 1997; Walczak et al., 1997; Wu et al., 1997) . Normal cells also express TRAIL receptors but they appear to be protected from TRAIL-mediated killing through competition for ligand binding by two decoy receptors, TRID (Degli-Esposti et al., 1997a; MacFarlane et al., 1997; Pan et al., 1997; Schneider et al., 1997; Sheridan et al., 1997) and TRUNDD (Degli-Esposti et al., 1997b; Marsters et al., 1997; Meng et al., 2000) . This level of complexity suggests that TRAIL induced apoptotic signaling may play an important role in the maintenance of normal tissues (Ashkenazi and Dixit, 1998; Nagata, 1997) .
It is clear that programmed cell death includes signaling through the cell surface by ligands such as FAS, TNF or TRAIL that bind to death receptors, as well as signals within the cell that promote mitochondrial cytochrome c release which can be inhibited by bcl2 (Ashkenazi and Dixit, 1998; Green and Reed, 1998; Nagata, 1997) . The end result of these signaling pathways is widespread proteolysis and endonucleolytic cleavage of chromosomal DNA, events that characterize the apoptotic phenotype. The apoptotic cascade is also a ®nal common pathway of cell death following exposure to chemotherapy or radiotherapy. It is becoming clear that the p53-dependent apoptosis which occurs following exposure of cells to cytotoxic chemotherapeutic drugs involves multiple inter-related signaling pathways which can all lead to death.
The ®rst targets of p53 to be implicated in death signaling were bax and Fas/APO1 Miyashita and Reed, 1995; MuÈ ller et al., 1998) . It is now known that these eectors signal through dierent mechanisms which ultimately lead to apoptosis. Bax signaling includes steps that involve the release of cytochrome c from the mitochondria and this can trigger activation of initiator caspase 9 and downstream executioners, such as capsase 3 leading to apoptosis. The Fas/APO1 signal is transmitted through the Fasassociated death domain (FADD) adaptor which recruits initiator capase 8 and 10 thus triggering the apoptotic cascade. Although it can be shown that these targets may be involved in p53-dependent death, neither bax nor Fas/APO1 are absolutely required. However, it has been recently shown that Fas/APO1 has a sequencespeci®c DNA-binding site for p53 (MuÈ ller et al., 1998) , indicating that wt-p53 can directly regulate FAS/APO1 expression. Several screens for p53 targets in cells undergoing apoptosis following p53 activation by DNA-damaging chemotherapy or p53 over-expression following Ad-p53 infection have led to the isolation of several novel targets (see for recent review). IGF-BP3 and PIG3 appear to be directly regulated by p53 through sequence-speci®c DNA binding (Polyak et al., 1997) . Another screen using the cytotoxic drug doxorubicin to induce p53 dependent apoptosis led to the isolation of the KILLER/DR5 proapoptotic TRAIL receptor gene as a p53-upregulated target (Wu et al., , 1999b . Although these observations indicated that KILLER/DR5 may be directly controlled by p53, the evidence has remained 5 Figure 1 Identi®cation of p53 DNA-binding sites in the human KILLER/DR5 genomic locus. (a) p53 DNA-binding assay using fragments cloned by immunoselection. The 3-5E7-2, 3-5A3 and 3-13D16 clones were tested for the presence or absence of binding to wt-p53. For each clone, the DNA was tested for binding to wt-p53 (P) or a LacZ control (L), adjacent to a control (C) lane containing 2% of the total end-labeled DNA used available for binding. An intensity of 42% following immunoprecipitation was considered`positive' in our screen . MG15 and PG13 fragments (obtained HindIII digestion of MG15-Luc and PG13-Luc, respectively) were used as negative and positive controls respectively. (b) Mapping of isolated p53-binding DNA fragments on the KILLER/DR5 genomic locus. DNA sequencing revealed that each fragment has high homology (as indicated, %) to the p53 consensus DNA-binding sequence. (c) DNA sequencing data of 3-5A3 fragment including Exon 1 through Intron 1 of the KILLER/DR5 genomic DNA. Restriction enzyme sites are indicated by arrows p53 regulates transcription of KILLER/DR5 R Takimoto and WS El-Deiry unclear. In this study, we used a modi®ed p53-binding and immunoselection strategy to explore whether KILL-ER/DR5 is indeed a direct target of p53-dependent transactivation.
Results
Identification of p53 DNA-binding sites in the KILLER/ DR5 genomic locus
In order to ®nd possible p53 DNA-binding consensus response elements within the KILLER/DR5 gene, a recombinant P1 clone comprising the entire human KILLER/DR5 genomic locus was subjected to an immunoselection protocol, which speci®cally enriches DNA fragments containing highanity p53-binding sites Zauberman et al., 1993 Zauberman et al., , 1995a . To isolate the fragments, we used p53-null Saos2 cells infected with Ad-p53 as the source of p53 protein and extracts from Ad-LacZ infected Saos2 as a control. After screening 25 pools by the p53 DNA-binding assay, we found three positive clones that appeared to bind to human p53 protein ( Figure 1 ). Digestion of the enriched plasmids revealed that the size of the three positive fragments were 0.66, 0.19 and 0.13 Kb, respectively ( Figure 1a ). DNA sequencing and Southern blotting (not shown) revealed that these fragments were located within a PstI fragment containing the KILLER/DR5 1st three coding exons (Pai et al., 1998; Wu et al., 1997) (Figure   1b ,c). Each fragment had 75 ± 90% homology to the p53 consensus DNA-binding sequence (Figure 1b) . Interestingly, the fragment which exhibited the highest homology was located in Intron I of KILLER/DR5 gene ( Figure 1b) . We also found that there was a TATA box located 17 bp upstream of the ATG site. These results indicate that p53 DNA-binding elements exist within the regulatory region of the human KILLER/DR5 gene.
P53-dependent promoter activation by the BS2 site in the KILLER/DR5 genomic locus
To examine which of the KILLER/DR5 genomic DNA-binding sites can mediate p53-dependent transcriptional activation, several luciferase-based reporter plasmids which had one or two copies of each of the three p53 DNA-binding sites were constructed and assayed by transient transfection in SW480 cells in the presence or absence of exogenous wt-p53. A schematic drawing of the relevant plasmids used for this purpose is presented in Figure 2a . These results revealed that only plasmid PG-BS2 showed transciptional activation of a basal polyoma promoter in the presence of wt-p53. Compared with PG13 which has 13 copies of a p53 consensus sequence (El-Deiry et al., 1993) , the induction rate of PG-BS2 was approximately 10%. A single copy of any of the three binding sites cloned as a 20 bp fragment upstream of the basal polyoma promoter did not confer p53 responsiveness upon the luciferase reporter (not shown). Moreover, BS1 and (7) or pCEP4-p53 (+). After 24 h of transfection, cells were harvested and luciferase activity was quantitated using a luminometer as described previously (Zeng et al., 1997)
Oncogene p53 regulates transcription of KILLER/DR5 R Takimoto and WS El-Deiry BS3 served as extremely poor activators of polyomadriven luciferase gene expression even when cloned as a tandem repeat present as two copies ( Figure 2 ). Thus these results led us to further investigate the regulation of the KILLER/DR5 gene by the BS2.
Localization of p53-dependent activation within the endogenous KILLER/DR5 genomic locus to the BS2 region
Based on the results from the initial reporter assays, we next tried to focus on the BS2 using genomic fragments of KILLER/DR5 by transient transfection. Since we found several restriction enzyme sites in the KILLER/ DR5 genomic locus (Figure 1c ), we constructed several plasmids which contained various combinations of binding sites as shown in Figure 3a . We found that only the plasmids which contained the BS2 site showed activation of the endogenous KILLER/DR5 promoterreporter gene in a p53-dependent manner (Figure 3b) . Furthermore, the full genomic fragment, pGL2-full, appeared capable of inducing the transactivation of KILLER/DR5 without an exogenous promoter even in the absence of p53. Thus, this fragment contains basal promoter activity and BS2 appears essential for induction of KILLER/DR5 by exogenous p53 (Figure 3b ). We suspected that additional sequences surrounding BS2 may be required to confer p53 responsiveness upon a basal promoter. The pGL2-SmaI construct contains BS2 as a 70 bp fragment. This region, present as a single copy, was sucient to confer p53 responsiveness upon the basal promoter from SV40 ( Figure 3b ).
Mutation of BS2 abrogates the p53-dependent activation of the KILLER/DR5 promoter-reporter gene
To con®rm that BS2 is responsible for the p53-dependent transactivation of the KILLER/DR5 gene, we introduced point mutations within the BS2 sequence of pGL2-Full. We changed two nucleotides within the consensus sequence of BS2 which are highly conserved in the ten base-pair half-site (El-Deiry et al., (Figure 4a ). We ®rst examined whether this mutation can aect the binding to p53 using an electrophoretic mobility shift assay. As shown in Figure 4b , mt BS2 lost the ability to bind to p53. Then we examined the transcriptional activity in the presence or absence of wt-p53 using SW480 cells. As shown in Figure 4c , the construct which has point mutations within BS2 showed no transcriptional stimulation by wt-p53. However, the Full-mt reporter retained basal promoter activity. Thus, we conclude that BS2 is responsible for the p53-dependent transactivation of the KILLER/DR5 gene.
E6 and mutant p53 inhibit p53-dependent transactivation of KILLER/DR5 promoter-reporter gene expression
Because it has been shown that human papilloma virus E6 targets p53 for degradation (Tsang et al., 1995) and that certain mutant p53 (mt-p53) proteins can have a dominant eect on wt-p53, we investigated whether these factors could abrogate the p53-dependent transcriptional activation of the KILLER/DR5 genomic reporter. We examined the KILLER/DR5 genomic reporter in two dierent wt-p53 expressing cell lines transfected with pCMV-E6 and its parental pCMV-neo vector (Wu and El-Deiry, 1996) . As shown in Figure  5a , the luciferase activity of both HCT116-E6 (colon carcinoma) and H460-E6 (non-small cell lung carcinoma) showed lower activity than the matched neotransfected cell lines (Figure 5a, upper panel) . Western blotting for p53 revealed that the expression level of p53 was diminished in the E6-transfected cells ( Figure  5a , lower panel), indicating that the E6 mediated reduction in transcription of the KILLER/DR5 was likely due to endogenous p53 degradation. We believe the residual reporter activity is most likely due to basal activation of the KILLER/DR5 promoter by factors other than p53. To verify the eect of E6 and mutant p53 on the transcriptional regulation of KILLER/ DR5, we used the HCT116 parental cell line and transiently transfected with pCEP4-mt-p53 (A273H) or pCMV-E6. As shown in Figure 5b , both mt-p53 (A273H) and E6 decreased the induction of KILL-ER/DR5 transactivation by at least 50% in pGL2-full transfected-cells (Figure 5b ). Western blot analysis revealed that this induction was obviously dependent on the expression of p53 (Figure 5c ). Our observations suggest that p53-dependent transactivation of KILL-ER/DR5 can be inhibited by E6 and mt-p53, which may contribute to a defective apoptotic response.
Doxorubicin can enhance the induction of the KILLER/ DR5 promoter-reporter gene in a p53-dependent manner associated with enhanced binding to BS2
It has been shown that the DNA damaging agent doxorubicin can induce the stabilization of p53 (Lowe et al., 1993) , and p53-dependent KILLER/DR5 Reporter assay using wt and mutant BS2 genomic KILLER/DR5 region in the presence or absence of exogenous wt-p53 in SW480 cells. PGL2 is the promoterless luciferase vector backbone control mRNA upregulation ). Therefore, we tested whether doxorubicin can induce the transactivation of the KILLER/DR5 by wt-p53. We tested the eect of doxorubicin-treatment on wt-p53-binding to BS2 using several cell lines with dierent endogenous p53 status. As shown in Figure 6a , EMSA revealed that only wt-p53 expressing cell lines could exhibit DNA-p53 binding following doxorubicin treatment (compare lane 10 vs 9 and lane 14 vs 13). Cell lines with mutant, degraded or no p53 showed no mobility shift using the KILLER/DR5 BS2 probe. We next determined the eect of doxorubicin on the activation of KILLER/DR5 transcription using reporter plasmids as a function of p53 status. As shown in Figure 6b , the transactivation of the KILLER/DR5 gene was upregulated by exogenous p53 and doxorubicin was eective in enhancing the reporter activity. Thus, doxorubicin appears to promote the transactivation of the KILLER/DR5 gene via a p53-dependent pathway.
Discussion
To examine whether p53 directly transactivates the KILLER/DR5 gene in a manner similar to its eects on Fas/APO1 (MuÈ ller et al., 1998), p21 WAF1 (El-Deiry et al., 1993 , gadd45 (Kastan et al., 1992; Smith et al., 1994) , mdm2 (Juven et al., 1993; Wu et al., 1993; Zauberman et al., 1993 Zauberman et al., , 1995a , cyclinG (Okamoto and Beach, 1994; Zauberman et al., 1995b) , Cathepsin D , EGF (Sheikh et al., 1997) and Bax (Miyashita et al., 1994; Miyashita and Reed, 1995) , we searched for p53 responsive elements in the KILLER/DR5 gene. As a result, direct cloning of p53 binding elements from the human KILLER/ DR5 genomic locus yielded three DNA fragments containing p53-binding sites within an intronic sequence (Figure 1 ). There is precedent for intronic p53 responsive elements in targets Fas/APO1 (MuÈ ller et al., 1998), gadd45 (Kastan et al., 1992; Smith et al., 1994) , and mdm2 (Juven et al., 1993; Wu et al., 1993; , 1993, 1995a) . The intronic BS2 site showed the highest degree of homology with the p53 consensus sequence and this correlated with the strongest transactivation among the three sites. Although we showed that mutating BS2 abolishes p53-responsiveness, we cannot rule out the possibility that BS1 and BS3 may be involved in mediating p53-dependent activation of the KILLER/ DR5 under certain circumstances. The 3.6 Kb genomic regulatory region of the KILL-ER/DR5 gene showed basal transcriptional activity. We believe that similar to other p53 targets such as GADD45 or mdm2 the intronic site may function as an enhancer element in the presence of activated p53 (Juven et al., 1993; Wu et al., 1993; Zauberman et al., 1993) .
The observation that the KILLER/DR5 gene can only be transactivated by wt-p53 but not tumorderived mutant p53 argues that the KILLER/DR5 gene may be an important target for apoptosis induction by p53 during tumor suppression. Further investigations are needed in view of the more than 150 dierent p53 mutations demonstrated in human cancers so far to characterize the kind of mutations that lead to loss of the ability of p53 to act as a transcription factor of the KILLER/DR5 gene.
The fact that wt-p53 has a stimulatory eect on KILLER/DR5 gene activity, whereas the investigated mt-p53 protein and E6 are not capable of activating the KILLER/DR5 gene, may explain why mutations in p53 contribute to tumor progression and resistance of cancer cells to chemotherapy. It has been reported that the KILLER/DR5 gene is regulated by a p53-independent pathway (Sheikh et al., 1998). Our observations with mt-p53 and E6 are consistent with the idea that the basal activity of the KILLER/DR5 promoter may be regulated by p53-independent mechanisms. In this regard, our KILLER/DR5 promoter-reporter plasmids should be helpful in identifying other regulators of KILLER/DR5 gene expression, modi®ers of p53-dependent KILLER/DR5 expression and to screen for agents that may induce the KILLER/DR5 gene expression via p53-independent pathways (Wu et al., 1999a) .
Since detailed analysis of KILLER/DR5 expression in both cancer cells and human development is still unknown, we believe cloning of the promoter region provides a useful tool to study the expression of the KILLER/DR5 gene during embryonic development and during cancer progression.
Taken together, these results suggest, in part, that wt-p53-induced apoptosis may be dependent on the induction of the KILLER/DR5 gene. Interference of anticancer drugs with apoptosis pathways can take place at several levels, including accumulation of wtp53, triggering of KILLER/DR5 receptors and Fas/ APO1, stimulation of signaling cascades, and activation of caspases, thus aecting the balance of apoptotic and antiapoptotic signaling. Studies to understand the regulation of transcription of the KILLER/DR5 gene may lead to the development of novel strategies to trigger cancer cell apoptosis.
Materials and methods

Cell lines
The wild-type p53-expressing human non-small cell lung cancer cell line H460, a gift from Dr SB Baylin (John Hopkins University), human colon cancer cell line HCT116 Figure 6 Eect of Doxorubicin on the induction of the KILLER/DR5 promoter-reporter gene. (a) Various wt, mutant, null or degraded p53 expressing cell lines (as indicated) were treated with 0.2 mg/ml doxorubicin for 20 h. After treatment, cells were harvested to collect nuclear extracts which were then subjected to EMSA for p53 binding.`L' and`P' represent (7) and (+) controls using extracts derived from Saos2 cells infected by Ad-LacZ and Ad-p53, respectively, followed by EMSA using labeled BS2 as a probe. (b) SW480 cells were co-transfected with 1 mg of reporter plasmids and pGL2-Full. After 4 h of transfection, cells were treated with 0.2 mg/ml of doxorubicin for 20 h, and harvested for measuring luciferase activity and p53-null human osteosarcoma cell line Saos2 was maintained in culture as previously described . The mutant p53-expression human colon cancer cell line SW480 was passaged as previously described (Zeng and El-Deiry, 1996) . Doxorubicin treatment was performed as described .
p53 DNA-binding assay DNA of a P1 clone which contains the KILLER/DR5 genomic DNA (Pai et al., 1998; Wu et al., 1997) was digested to completion with Sau3AI. The mixture of small DNA fragments was litigated into the BamHI site of pBlueScript II KS+ (Stratagene) and the ligation products were transformed into Escherichia Coli. The resultant colonies were separated into 25 subpools which contained 20 ± 30 colonies each for p53-binding assay. The procedure of p53-DNA binding assay was similar to that described by Zaubermann et al. (1993 Zaubermann et al. ( , 1995a , except that the nuclear extracts used for selection were prepared from Saos2 cells infected with Ad-p53 and harvested at 24 h after infection. In brief, individual clones were tested for p53 DNAbinding after cleavage with BamHI and end-labeling by Klenow ®ll-in. A total of 10 ng of labeled DNA were incubated with 1 mg of total nuclear extracts obtained from Saos2 cells infected with Ad-p53 or Ad-LacZ at 50 MOI and 100 ng of poly dI-dC at 48C for 30 min in 100 ml of DNA binding buer containing 100 mM NaCl, 20 mM Tris-HCl, pH 7.0, 10% glycerol, 1% NP-40 and 5 mM DTT. DNA fragments bound to p53 were complexed to antibodies by the addition of 8 ml containing 400 ng each of the anti-p53 antibodies pAb421 and pAb1801 (Oncogene Science), and incubated for 30 min at 48C. The DNA-p53-anti-p53 antibody complexes were precipitated following the addition of 20 ml of DNA-binding buer containing 1 mg resuspended protein A Sepharose beads (Pharmacia) and 10 mg of poly dI-dC and incubation at 48C for 30 min. After removal of the supernatant, the immunoprecipitate was washed three times with 1 ml of DNA-binding buer. Bound DNA was puri®ed by treatment with SDS and proteinase K at 508C for 1 h, extracted with phenol and chloroform, precipitated with ethanol, separated by electrophoresis on a 7.5% nondenaturating gel, and visualized by autoradiography. After 25 rounds of p53 DNA-binding assays, positive clones were then subjected to direct DNA sequencing using a T7 sequenase Kit (USB) according to the manufacturer's instruction.
Plasmids
The p53-speci®c reporter plasmids PG13-Luc, MG15-Luc (El-Deiry et al., 1993) , the wild-type p53 expression vector pCEP4-p53 (El-Deiry et al., 1993) and the mutant p53 (A273H) expression vector were provided by B Vogelstein (Johns Hopkins University). The HPV-E6 expressing vector (Wu and El-Deiry, 1996 ; pCMV-E6) was kindly provided by Dr Kathleen Cho (University of Michigan). To make the PG-BS1, -BS2 and -BS3 vectors, synthetic oligomers were used; 5'-cttaggcgtggtggtgcaggcctataggcgtggtggtgcaggcctttg-3' and 5'-aattcaaaggcctgcaccaccacgcctataggcctgcaccaccacgcctaaggtac-3' for BS1, 5'-cttgggcatgtccgggcaagacgatgggcatgtccgggcaagacgttg-3' and 5'-aattcaacgtcttgcccggacatgcccatcgtcttgcccggacatgcccaaggtac-3' for BS2, 5'-cttatccttgcagaagacatgtccatatccttgcagaagacatgtccttg-3' and 5'-aattcaa ggacatgtcttctgcaaggat atggacatgtctt ctgcaaggataaggtac-3' for BS3. After annealing and phosphorylation of these oligomers, the fragments were ligated with the polyoma virus basal promoter (Py) which was obtained from PG13-Luc as an EcoRI/HindIII fragment. The Py and binding site fragments were subcloned into the PG13-Luc vector after deletion of its p53 consensus sequence cassette as a KpnI/ HindIII fragment. The pGL2-PG13 vector was obtained by subcloning the HindIII fragments from PG13 into the pGL2-basic vector (Stratagene). To generate the pGL2-full, pGL2-SV-half, pGL2-SV-smaI, pGL2-SacIIA and SacIIB vectors, we used a 3.6 Kb Pst1 fragment from the KILLER/DR5 P1 clone which includes 1.6 Kb upstream of the ATG through Intron 2 in KILLER/DR5 genomic DNA (Pai et al., 1998) . Each fragment was subcloned into the pGL2-basic vector as a SacI/XhoI fragment as shown in Figure 3a . All of the vectors were con®rmed by DNA sequencing. To generate the mutation of BS2, a site directed mutagenesis kit (Quikchange, Stratagene) was used according to the manufacturer's instructions.
Transfections and reporter assays
Transfections were carried out as previously described (Zeng et al., 1997) . In brief before transfection, cells were seeded at 1610 6 cells/6 cm dish. The cells were transfected by Lipofectin-DNA conjugatges suspended in Opti-MEM serum-free media (Gibco-BRL). Serum containing media was added at 4 h after transfection. Cells were harvestted 24 h after transfection and assayed for luciferase and b-galactosidase activity as previously described (Oliner et al., 1993; Zeng et al., 1997) .
Western blotting
Immunoblotting was performed as previously described . Immunodetection was performed with mouse anti-human p53 monoclonal antibody pAb1801 (Oncogene Science), mouse anti-human p21 WAF1 monoclonal antibody EA10 (Oncogene Science) and goat anti-human Actin antibody (Santa-Cruz).
Electrophoretic mobility shift and supershift assays
The mouse anti-human p53 monoclonal antibody pAb421 (Ab1, Oncogene Science) was used to activate sequencespeci®c DNA-binding by p53 in electrophoretic mobility shift assays as previously described .
The double-stranded DNA probes which were used in the experiments contained the following sequences: the p21 promoter (5'-CAGGAACAGTCCCAACATGTTGAGC-3', site 1), wild-type BS2 (5'-GCCGGGCATGTCCGGGCAA-GACGCAC) and mutant BS2 (5'GCCGGGAATATCCG-GGCAAGACGCAC).
